A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.

Saved in:
Bibliographic Details
Title: A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.
Authors: Cook JA; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Patten PEM; Comprehensive Cancer Centre, Faculty of Life Sciences and Medicine, King's College London, London, UK., Peckham N; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Moss P; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Phillips N; Department of Haematology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK., Abhishek A; Academic Rheumatology, University of Nottingham, Nottingham, UK., Roberts T; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Hodges M; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Talbot G; Department of Haematology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK., Barber V; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Francis A; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Shields AM; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Duley L; CLL Support Association, London, UK., Hoogeboom R; Faculty of Life Sciences and Medicine, King's College London, London, UK., Willett BJ; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK., Scott S; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK., Parry-Jones N; Department of Haematology, Aneurin Bevan University Health Board, Abergavenny, UK., Eyre TA; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, UK., Plested G; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Vandici G; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Wandroo FA; Department of Haematology, Sandwell and West Birmingham Hospitals, NHS Trust, West Bromwich, UK., Hutchinson C; Department of Haematology, University Hospitals Plymouth NHS Trust, Plymouth, UK., Paneesha S; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Murray DJ; University Hospitals Coventry and Warwickshire, Coventry, UK., Martinez-Calle N; Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Jenkins S; Department of Haematology, The Dudley Group NHS Foundation Trust, Dudley, UK., Heartin E; Department of Haematology, Betsi Cadwaladr University Health Board, Bangor, UK., Parry HM; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. Electronic address: h.m.parry@bham.ac.uk.
Source: The Lancet. Haematology [Lancet Haematol] 2025 Apr; Vol. 12 (4), pp. e294-e303.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Equivalence Trial
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3026
DOI:10.1016/S2352-3026(25)00008-0